Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01212250 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv20
  2. Primary and study completion dates: Dec 1, 2020 to Dec 31, 2026v19
  3. Primary and study completion dates: Dec 1, 2018 to Dec 1, 2020v18
  4. Primary and study completion dates: Dec 2018 to Dec 1, 2018
    • Start date: Sep 2010 to Sep 1, 2010
    v17
  5. Primary and study completion dates: Dec 2017 to Dec 2018v16
Show 14 earlier versionsHide 14 earlier versions
  1. Primary and study completion dates: Dec 2016 to Dec 2017v15
  2. Secondary endpoints revised (3)
    • Site contact updated
    v14
  3. Re-verified, no change to tracked fieldsv13
  4. Primary completion date: Feb 2016 to Dec 2016
    • Study completion date: May 2016 to Dec 2016
    v12
  5. Study title shortened, about 2 wordsv11
  6. 2 versions Re-verified since Aug 21, 2015, no change to tracked fieldsv9-v10
  7. Site contact updatedv8
  8. Primary completion date: Feb 2014 to Feb 2016
    • Study completion date: May 2014 to May 2016
    v7
  9. 2 versions Re-verified since Mar 30, 2013, no change to tracked fieldsv5-v6
  10. Primary completion date: Feb 2012 to Feb 2014
    • Study completion date: May 2012 to May 2014
    • Site contact updated
    v4
  11. 2 versions Re-verified since Apr 11, 2011, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.
Trial Details
NCT Number NCT01212250
Lead Sponsor Institute of Liver and Biliary Sciences, India
Conditions
(from sponsor)		 Cirrhosis
Related terms Fibrosis
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov